AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$BLTE

Scholl Hendrik Peter sold $83K of BLTE (indirect holdings)

Scholl Hendrik Peter (Chief Medical Officer) sold 500 indirectly-held shares of BELITE BIO, INC (BLTE) at an average of $165.32 ($163.62–$170.02) across 8 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Scholl Hendrik Peter
Published Oct 5, 2026, 11:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Bearish
high confidence
Mentioned
$BLTE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTEBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a lack of confidence, potentially nudging the stock lower.

02

Market read

A modest insider sell by a senior executive; likely limited but negative short‑term impact.

03

What to watch

Potential upcoming clinical data releases or partnership news may offset the negative signal.

Relevance 2/10Novelty 2/10Timing: today

Background

Form 4 filing by BELITE BIO's Chief Medical Officer discloses an open‑market sale of 500 shares.

Company-level read

Ticker impact

$BLTEBearishHigh confidence
Context

Chief Medical Officer sold 500 shares for $82,658 via a 10b5-1 plan, reducing his stake to 14,500 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

Form 4 filing is a primary source; the sale size is modest but the CMO role adds significance.

Market effects

Sector

Minimal impact on the broader biotech sector; insider sales are common and usually company‑specific.

Regional

No regional effect; the filing is U.S.‑focused.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • company
    BELITE BIO, INC

    Biotech firm focused on oncology therapeutics.

  • insider
    Scholl Hendrik Peter

    Chief Medical Officer of BELITE BIO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

SEP 4
$BLTEMedAI 8/10

Belite Bio (BLTE) Is Up 9.0% After FDA Grants Priority Review To Tinlarebant Stargardt NDA

Belite Bio (BLTE) shares rose 9.0% after the FDA granted priority review to its new drug application for tinlarebant, a treatment for Stargardt disease. The company expects a decision by February 12, 2027, and is preparing for commercial launch, targeting 53,000 patients. Phase III data showed a 35.7% reduction in lesion growth versus placebo. The company projects $563.2 million revenue and $318.3 million earnings by 2029, a 24% upside to its current price.

simplywall.st3 min
AUG 12
$BLTEMedAI 8/10

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio (BLTE) said the FDA accepted its tinlarebant NDA for Stargardt disease type I and granted priority review. A decision is expected Feb. 12, 2027. Priority review targets action in six months. The filing is based on Phase III DRAGON results showing a 35.7% reduction in atrophic lesion growth rate vs placebo. BLTE shares rose about 6.2% on Tuesday.

tradingview.com4 min
AUG 12
$BLTEMedAI 8/10

Belite Bio lands priority review for first Stargardt treatment

The FDA accepted and granted priority review to Belite Bio’s (Nasdaq: BLTE) New Drug Application for tinlarebant to treat Stargardt disease type 1. The Prescription Drug User Fee Act target action date is Feb. 12, 2027. The program previously received breakthrough therapy, fast track, and rare pediatric designations, and has orphan drug status in multiple regions.

thepharmaletter.com4 min
JUL 20
$BLTEMedAI 8/10

Why Is Belite Bio Stock Gaining Monday? - Belite Bio (NASDAQ:BLTE)

Belite Bio (NASDAQ:BLTE) reported additional secondary endpoint statistics from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The company said qAF stayed stable or fell about 2% at 25 months with tinlarebant versus about a 20% increase with placebo, and the trial previously met its primary endpoint, reducing retinal lesion growth by 35.7% versus placebo. BLTE shares rose about 3.11% to $154.74.

benzinga.com4 min